Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Retatrutide , developed by Eli Lilly, is a novel triple agonist that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion
Almahariq, M., Mei, F
Follow the prescribing information provided by your doctor
NoSemaglutide does not reduce steroid efficacy
In Phase 3 trials (n=412), it produced a 15.2% reduction in visceral fat and a significant increase in IGF-1 (Falutz et al., JAMA 2007At French Peptides, it is available exclusively for research
US$ 25.22
US$ 29.17
US$ 23.82
US$ 23.78
